Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE Trial | Zendy

Toby Pepperrell | Zendy; François Venter | Zendy; Kaitlyn McCann | Zendy; Bronwyn Bosch | Zendy; Melissa Tibbatts | Zendy; Joanna Woods | Zendy; Simiso Sokhela | Zendy; Celicia Serenata | Zendy; Michelle Moorhouse | Zendy; Ambar Qavi | Zendy; Andrew Hill | Zendy

Open Access

Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE Trial

Author(s) -

Toby Pepperrell,

François Venter,

Kaitlyn McCann,

Bronwyn Bosch,

Melissa Tibbatts,

Joanna Woods,

Simiso Sokhela,

Celicia Serenata,

Michelle Moorhouse,

Ambar Qavi,

Andrew Hill

Publication year - 2021

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciab086

Subject(s) - dolutegravir , human immunodeficiency virus (hiv) , medicine , virology , oncology , viral load , antiretroviral therapy

Following evidence of HIV RNA re-suppression on DTG-based regimens, we assess the re-suppressive capacity of ADVANCE participants on TAF/FTC+DTG, TDF/FTC+DTG, and TDF/FTC/EFV. Viraemic participants were able to re-suppress within 3 follow-up visits of protocol-defined virological failure (PDVF) in 77/121 (64%), 85/126 (67%), and 44/138 (32%) cases respectively (DTG regimens vs. TDF/FTC/EFV; P < 0.001).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research